Neuromyelitis optica News and Research

RSS

Drug reduces risk of relapse with neuromyelitis optica spectrum disorder, study shows

The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder.

3 May 2019

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

UT Southwestern scientists identify gene mutation linked with perplexing brain condition

Scientists conducting one of the largest full DNA analyses of a rare disease have identified a gene mutation associated with a perplexing brain condition that blinds and paralyzes patients.

20 Jun 2018

Popular allergy drug may reduce relapses in patients with neuromyelitis optica

The addition of cetirizine (the popular allergy medication sold under the brand name Zyrtec) to standard therapy is safe, well-tolerated, and may reduce relapses in patients with neuromyelitis optica (NMO), a rare and severe disease that causes inflammation and demyelination (damage to the myelin - the protective coating of nerve cells), primarily in the optic nerve (optic neuritis), spinal cord (myelitis), and brainstem.

2 Feb 2018

Study: Most patients with unknown spinal cord inflammation have alternative, specific diagnosis

A study by Mayo Clinic researchers found that most patients with suspected spinal cord inflammation of unknown cause have an alternative, specific diagnosis.

10 Jan 2018

Mayo Clinic launches new clinical test that distinguishes IDDs from multiple sclerosis

Mayo Clinic has launched a first-in-the-U.S. clinical test that will help patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.

28 Nov 2017

Unique microscope reveals clues to destructive autoimmune disease

Using a unique microscope capable of illuminating living cell structures in great detail, researchers at the University of Colorado Anschutz Medical Campus have found clues into how a destructive autoimmune disease works, setting the stage for more discoveries in the future.

26 Apr 2017

Study highlights possible reasons for MS misdiagnosis

A number of common conditions are mistaken for multiple sclerosis (MS), a disabling central nervous system disease, say researchers at four academic medical centers across the U.S in a study published online August 31, 2016 in the journal Neurology.

1 Sep 2016

Rare DNA alteration may increase rsk of multiple sclerosis

Scientists at the University of British Columbia and Vancouver Coastal Health have proven that multiple sclerosis (MS) can be caused by a single genetic mutation - a rare alteration in DNA that makes it very likely a person will develop the more devastating form of the neurological disease.

6 Jun 2016

Medical professionals compare different treatment methods for Neuromyelitis optica

In the course of a study conducted throughout Germany, medical professionals have compared different treatment methods for Neuromyelitis optica, an inflammatory disease of the central nervous system. It turned out that the best results were not achieved with conventional steroid therapy. Under the auspices of the Ruhr-Universität Bochum and the Hannover Medical School, the team published their findings in the journal Annals of Neurology.

30 Nov 2015

Medical professionals compare different treatment options for Neuromyelitis optica

26 Nov 2015

Escalation therapy for neuromyelitis attacks improves remission rates

Researchers recommend escalating patients’ therapy in the event of continuing attacks of neuromyelitis optica, basing sequential treatment on the type of attack and prior treatment response.

16 Nov 2015

Cryoport to support future clinical trials for Opexa's personalized T-cell immunotherapy programs for MS, NMO

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' lead personalized T-cell immunotherapy programs for Multiple Sclerosis ("MS") and Neuromyelitis Optica ("NMO").

27 Aug 2015

International consensus panel reviews new diagnostic criteria for neuromyelitis optica spectrum disorder

New diagnostic criteria were introduced this week for neuromyelitis optica, now called neuromyelitis optica spectrum disorder, which is an inflammatory disease of the central nervous system that is sometimes mistaken for multiple sclerosis.

9 Jul 2015

Quadrivalent HPV vaccine cleared of multiple sclerosis risk

A study of almost 4 million girls and women allays fears that receipt of the quadrivalent human papillomavirus vaccine could increase the risk of developing multiple sclerosis, or other demyelinating disorders.

7 Jan 2015

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono.

7 Oct 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

Research findings may lead to new treatments, approaches for controlling multiple sclerosis

Scientists are gaining a new level of understanding of multiple sclerosis that may lead to new treatments and approaches to controlling the chronic disease, according to new research released today at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

10 Nov 2013

Viropharma announces financial results for third quarter 2013

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012.

31 Oct 2013